These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab. Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697 [No Abstract] [Full Text] [Related]
5. [Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study]. Lieutenant V; Toulza É; Pommier M; Lortal-Canguilhem B Bull Cancer; 2015 Mar; 102(3):270-6. PubMed ID: 25725921 [TBL] [Abstract][Full Text] [Related]
6. As treatment options progress, so must we. Harmer V Br J Nurs; 2013 May 23-Jun 12; 22(10):S3. PubMed ID: 23752364 [No Abstract] [Full Text] [Related]
7. Reply to the letter to the editor 'patients' preference and informed consent' by Pumo et al. Pivot X; Machackova Z Ann Oncol; 2015 Jun; 26(6):1269-1270. PubMed ID: 25787922 [No Abstract] [Full Text] [Related]
9. Can NOAH guide us to improved survival in breast cancer? Johnston SR Lancet Oncol; 2014 May; 15(6):550-2. PubMed ID: 24657002 [No Abstract] [Full Text] [Related]
10. Is there an ideal way to combine trastuzumab with chemotherapy? Gonzalez-Angulo AM; Hortobagyi GN J Clin Oncol; 2011 Dec; 29(34):4474-6. PubMed ID: 22042935 [No Abstract] [Full Text] [Related]